vTv Therapeutics (VTVT) Competitors $14.96 +0.44 (+3.03%) (As of 12/20/2024 05:17 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends VTVT vs. OPT, PRQR, AMRN, ALEC, ADCT, CHRS, GOSS, OGI, GNFT, and IPHAShould you be buying vTv Therapeutics stock or one of its competitors? The main competitors of vTv Therapeutics include Opthea (OPT), ProQR Therapeutics (PRQR), Amarin (AMRN), Alector (ALEC), ADC Therapeutics (ADCT), Coherus BioSciences (CHRS), Gossamer Bio (GOSS), Organigram (OGI), Genfit (GNFT), and Innate Pharma (IPHA). These companies are all part of the "pharmaceutical products" industry. vTv Therapeutics vs. Opthea ProQR Therapeutics Amarin Alector ADC Therapeutics Coherus BioSciences Gossamer Bio Organigram Genfit Innate Pharma vTv Therapeutics (NASDAQ:VTVT) and Opthea (NASDAQ:OPT) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, media sentiment, community ranking, dividends and earnings. Do insiders & institutionals believe in VTVT or OPT? 17.5% of vTv Therapeutics shares are owned by institutional investors. Comparatively, 56.0% of Opthea shares are owned by institutional investors. 1.3% of vTv Therapeutics shares are owned by insiders. Comparatively, 3.2% of Opthea shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has stronger valuation & earnings, VTVT or OPT? vTv Therapeutics has higher revenue and earnings than Opthea. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatiovTv Therapeutics$1M47.72-$20.25M-$4.53-3.30Opthea$124.67K1,564.49-$220.24MN/AN/A Does the MarketBeat Community prefer VTVT or OPT? vTv Therapeutics received 335 more outperform votes than Opthea when rated by MarketBeat users. Likewise, 57.80% of users gave vTv Therapeutics an outperform vote while only 53.13% of users gave Opthea an outperform vote. CompanyUnderperformOutperformvTv TherapeuticsOutperform Votes35257.80% Underperform Votes25742.20% OptheaOutperform Votes1753.13% Underperform Votes1546.88% Do analysts prefer VTVT or OPT? vTv Therapeutics presently has a consensus target price of $35.00, indicating a potential upside of 133.96%. Opthea has a consensus target price of $12.00, indicating a potential upside of 259.28%. Given Opthea's stronger consensus rating and higher probable upside, analysts clearly believe Opthea is more favorable than vTv Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score vTv Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Opthea 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Does the media refer more to VTVT or OPT? In the previous week, Opthea had 4 more articles in the media than vTv Therapeutics. MarketBeat recorded 5 mentions for Opthea and 1 mentions for vTv Therapeutics. vTv Therapeutics' average media sentiment score of 0.49 beat Opthea's score of 0.24 indicating that vTv Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment vTv Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Opthea 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Is VTVT or OPT more profitable? Opthea's return on equity of 0.00% beat vTv Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets vTv TherapeuticsN/A -184.64% -47.29% Opthea N/A N/A N/A Which has more risk & volatility, VTVT or OPT? vTv Therapeutics has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500. Comparatively, Opthea has a beta of 1.07, meaning that its stock price is 7% more volatile than the S&P 500. SummaryOpthea beats vTv Therapeutics on 10 of the 15 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.>> Register for the Workshop Now Get vTv Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VTVT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VTVT vs. The Competition Export to ExcelMetricvTv TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$46.31M$6.57B$5.13B$9.07BDividend YieldN/A2.99%5.08%4.23%P/E Ratio-3.3010.4289.5817.17Price / Sales47.72195.801,116.12116.95Price / CashN/A57.1642.8237.86Price / Book-1.615.094.774.78Net Income-$20.25M$151.83M$120.15M$225.60M7 Day Performance-0.47%-2.13%-1.92%-1.23%1 Month Performance-0.80%-3.10%11.47%3.36%1 Year Performance69.81%11.54%30.54%16.60% vTv Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VTVTvTv Therapeutics2.0072 of 5 stars$14.96+3.0%$35.00+134.0%+70.4%$46.31M$1M-3.309Gap UpOPTOpthea2.5742 of 5 stars$3.34+2.8%$12.00+259.3%+31.5%$195.04M$124,666.000.008Analyst UpgradeNews CoveragePRQRProQR Therapeutics2.2298 of 5 stars$2.38-15.9%$7.60+219.3%+34.2%$194.40M$7.05M-8.13180Gap DownHigh Trading VolumeAMRNAmarin0.0303 of 5 stars$0.47+3.8%N/A-42.6%$194.00M$241.02M-5.06360Analyst ForecastALECAlector4.2493 of 5 stars$1.98+0.5%$4.00+102.0%-76.4%$193.91M$61.51M-1.16270Analyst DowngradeADCTADC Therapeutics3.0937 of 5 stars$2.00+5.8%$8.00+300.0%+51.9%$193.38M$70.72M-0.86310Gap UpCHRSCoherus BioSciences4.0914 of 5 stars$1.68+4.0%$5.38+220.9%-21.6%$192.98M$304.34M-20.13246GOSSGossamer Bio3.6227 of 5 stars$0.85-8.6%$9.20+982.1%-1.4%$192.66M$105.32M-2.61180OGIOrganigram0.7654 of 5 stars$1.53+3.0%N/A+27.9%$192.39M$120.01M-3.65860Earnings ReportAnalyst RevisionNews CoverageGNFTGenfit1.2039 of 5 stars$3.80-0.5%$13.00+242.1%+2.2%$189.96M$41.31M0.00120Positive NewsIPHAInnate Pharma2.7604 of 5 stars$2.30-23.8%$11.50+400.0%-23.5%$186.22M$24.85M0.00220News CoverageGap DownHigh Trading Volume Related Companies and Tools Related Companies OPT Alternatives PRQR Alternatives AMRN Alternatives ALEC Alternatives ADCT Alternatives CHRS Alternatives GOSS Alternatives OGI Alternatives GNFT Alternatives IPHA Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:VTVT) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding vTv Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share vTv Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VTVT Stock Alerts